Close
  • Home

Archive - August 2020

ADC Digest - August 2020

ADC Digest - August 2020

Antibody–drug conjugates (ADCs)

ADC ‘s are the next generation “targetted” missiles being built in different shapes and forms to attack the enemy in a multitude of ways. What is an ADC – its is a monoclonal antibody tethered to a payload via a chemical linker. They lack the complexity of CAR-Ts, but have their own “improvement” areas. It will be a new weapon in our armamentarium. In the span of 2 weeks we saw both GlaxoSmithKline and AstraZeneca moving ahead with their ADC programs. Read more, tile wise below

Regulatory
SYS6043 granted BTD in China for the treatment of platinum-resistant Ovarian cancer
3 July 2026
Regulatory
Glenmark advances phase 3 trial of Trastuzumab rezetecan in platinum-resistant Ovarian cancer
3 July 2026
Regulatory
NMPA accepts Tecotabart Vedotin NDA for third-line CLDN18.2+ Gastric cancer
26 June 2026
Regulatory
Zai Lab’s Zocilurtatug pelitecan receives EMA Orphan Drug Designation for pulmonary Neuroendocrine carcinoma
19 June 2026
Regulatory
FDA accepts sBLA for Genentech’s Lunsumio and Polivy combination in relapsed/refractory Large B-cell lymphoma
19 June 2026
Regulatory
Oncopeptides submits EMA application for Pepaxti label expansion to third-line treatment
19 June 2026

Contact:

  info@ciscientists.com

 +1-908-212-7484

Optimal Dose

For a subscription, please provide your email id